In this study, we first identified DHR as an anti-CAF drug candidate using reporter cells expressing Twist1 promoter-GFP and confirmed that DHR repressed tumor progression both in vitro and in vivo by deactivating CAFs. Here, TWIST1 is linked to neoplasm.